These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34140647)

  • 41. Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis.
    Reeve J; Maden M; Hill R; Turk A; Mahtani K; Wong G; Lasserson D; Krska J; Mangin D; Byng R; Wallace E; Ranson E
    Health Technol Assess; 2022 Jul; 26(32):1-148. PubMed ID: 35894932
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence and risk of polypharmacy among the elderly in an outpatient setting: a retrospective cohort study in the Emilia-Romagna region, Italy.
    Slabaugh SL; Maio V; Templin M; Abouzaid S
    Drugs Aging; 2010 Dec; 27(12):1019-28. PubMed ID: 21087071
    [TBL] [Abstract][Full Text] [Related]  

  • 43. SWEDEGENE-a Swedish nation-wide DNA sample collection for pharmacogenomic studies of serious adverse drug reactions.
    Hallberg P; Yue QY; Eliasson E; Melhus H; Ås J; Wadelius M
    Pharmacogenomics J; 2020 Aug; 20(4):579-585. PubMed ID: 31949290
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adverse drug reactions and polypharmacy in the elderly in general practice.
    Veehof LJ; Stewart RE; Meyboom-de Jong B; Haaijer-Ruskamp FM
    Eur J Clin Pharmacol; 1999 Sep; 55(7):533-6. PubMed ID: 10501824
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Polypharmacy in chronic diseases-Reduction of Inappropriate Medication and Adverse drug events in older populations by electronic Decision Support (PRIMA-eDS): study protocol for a randomized controlled trial.
    Sönnichsen A; Trampisch US; Rieckert A; Piccoliori G; Vögele A; Flamm M; Johansson T; Esmail A; Reeves D; Löffler C; Höck J; Klaassen-Mielke R; Trampisch HJ; Kunnamo I
    Trials; 2016 Jan; 17():57. PubMed ID: 26822311
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interventions to improve the appropriate use of polypharmacy for older people.
    Patterson SM; Hughes C; Kerse N; Cardwell CR; Bradley MC
    Cochrane Database Syst Rev; 2012 May; (5):CD008165. PubMed ID: 22592727
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevention of adverse drug reactions in hospitalized older patients with multi-morbidity and polypharmacy: the SENATOR* randomized controlled clinical trial.
    O'Mahony D; Gudmundsson A; Soiza RL; Petrovic M; Cruz-Jentoft AJ; Cherubini A; Fordham R; Byrne S; Dahly D; Gallagher P; Lavan A; Curtin D; Dalton K; Cullinan S; Flanagan E; Shiely F; Samuelsson O; Sverrisdottir A; Subbarayan S; Vandaele L; Meireson E; Montero-Errasquin B; Rexach-Cano A; Correa Perez A; Lozano-Montoya I; Vélez-Díaz-Pallarés M; Cerenzia A; Corradi S; Soledad Cotorruelo Ferreiro M; Dimitri F; Marinelli P; Martelli G; Fong Soe Khioe R; Eustace J
    Age Ageing; 2020 Jul; 49(4):605-614. PubMed ID: 32484850
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review.
    O'Shea J; Ledwidge M; Gallagher J; Keenan C; Ryan C
    Pharmacogenomics J; 2022 Mar; 22(2):89-99. PubMed ID: 35194175
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study.
    van der Wouden CH; Böhringer S; Cecchin E; Cheung KC; Dávila-Fajardo CL; Deneer VHM; Dolžan V; Ingelman-Sundberg M; Jönsson S; Karlsson MO; Kriek M; Mitropoulou C; Patrinos GP; Pirmohamed M; Rial-Sebbag E; Samwald M; Schwab M; Steinberger D; Stingl J; Sunder-Plassmann G; Toffoli G; Turner RM; van Rhenen MH; van Zwet E; Swen JJ; Guchelaar HJ;
    Pharmacogenet Genomics; 2020 Aug; 30(6):131-144. PubMed ID: 32317559
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Primun non nocere, polypharmacy and pharmacogenetics.
    Isidoro-García M; Sánchez-Martín A; García-Berrocal B; Román-Curto C
    Pharmacogenomics; 2015 Nov; 16(17):1903-5. PubMed ID: 26554320
    [No Abstract]   [Full Text] [Related]  

  • 51. Polypharmacy: America's other drug problem.
    Guharoy R
    Am J Health Syst Pharm; 2017 Sep; 74(17):1305-1306. PubMed ID: 28842459
    [No Abstract]   [Full Text] [Related]  

  • 52. District nurses' use of a decision support and assessment tool to improve the quality and safety of medication use in older adults: a feasibility study.
    Lagerin A; Lundh L; Törnkvist L; Fastbom J
    Prim Health Care Res Dev; 2020 Jun; 21():e15. PubMed ID: 32495732
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacogenetic content of commercial genome-wide genotyping arrays.
    Lemieux Perreault LP; Zaïd N; Cameron M; Mongrain I; Dubé MP
    Pharmacogenomics; 2018 Oct; 19(15):1159-1167. PubMed ID: 30272537
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development and pilot testing of PHARAO-a decision support system for pharmacological risk assessment in the elderly.
    Böttiger Y; Laine K; Korhonen T; Lähdesmäki J; Shemeikka T; Julander M; Edlert M; Andersson ML
    Eur J Clin Pharmacol; 2018 Mar; 74(3):365-371. PubMed ID: 29198061
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Prevention of adverse drug reactions in older patients].
    Burkhardt H; Wehling M; Gladisch R
    Z Gerontol Geriatr; 2007 Aug; 40(4):241-54. PubMed ID: 17701115
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Polypharmacy: a healthcare conundrum with a pharmacogenetic solution.
    Sharp CN; Linder MW; Valdes R
    Crit Rev Clin Lab Sci; 2019 Nov; 57(3):161-180. PubMed ID: 31680605
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A scoping review of polypharmacy interventions in patients with stroke, heart disease and diabetes.
    Lum MV; Cheung MYS; Harris DR; Sakakibara BM
    Int J Clin Pharm; 2020 Apr; 42(2):378-392. PubMed ID: 32319017
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Psychopharmacological Treatment in Older People: Avoiding Drug Interactions and Polypharmacy.
    Kratz T; Diefenbacher A
    Dtsch Arztebl Int; 2019 Jul; 116(29-30):508-518. PubMed ID: 31452508
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PM-TOM: A Method for Finding Personalized Polypharmacy Therapies with Minimal Adverse Drug-Drug, Drug-Gene and Drug-Condition Interactions.
    Kulenovic A; Lagumdzija-Kulenovic A
    Stud Health Technol Inform; 2020 Jun; 270():648-652. PubMed ID: 32570463
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cooperation between geriatricians and general practitioners for improved pharmacotherapy in home-dwelling elderly people receiving polypharmacy - the COOP Study: study protocol for a cluster randomised controlled trial.
    Romskaug R; Molden E; Straand J; Kersten H; Skovlund E; Pitkala KH; Wyller TB
    Trials; 2017 Apr; 18(1):158. PubMed ID: 28372591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.